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Reviews/Commentaries/Position Statements
C O M M E N T A R Y

Placebo-Controlled Trials of New Drugs:
Ethical Considerations
DAVID ORENTLICHER, MD, JD

M

uch controversy exists regarding
the ethics of placebo-controlled
trials in which an experimental
therapy will compete with an already established treatment (or treatments). In
such cases, argue critics, patients in the
control arm of the study should receive an
accepted therapy rather than a placebo.
By using an active and effective drug, the
control patients would not be placed at
risk for deterioration of their disease, and
the study would generate more meaningful results for physicians. The key question,
it is said, is not whether a new therapy is
better than nothing but whether it is better than the current standard of care (1,2).
In response, say proponents of placebo-controlled trials, critical information
cannot always be obtained by giving control patients an existing therapy. For some
effective therapies, the drug may perform
no better than placebo in a particular trial
even though other trials demonstrate the
drug’s superiority to placebo. If an experimental agent confers the same benefit as
such an existing therapy in a comparative
trial, we cannot be certain that the new
agent is any better than placebo. We
might have one of the trials in which the
existing therapy (and therefore the new
agent) does no better than placebo, perhaps because of inadequate sample size,
perhaps because the outcome measure
can vary widely from one patient group to
another (3–5). In addition, some new
therapies are useful even if they are less
effective than existing therapies. Some patients might choose a less effective drug if
substantial cost savings or a reduction in
side effects would be realized (6). Without a placebo control, however, one cannot always tell whether a new drug that is
not as effective as existing therapy is still

sufficiently more effective than placebo to
justify its use. Finally, not all established
therapies have been shown to be superior
to placebo. If newer drugs are compared
with the unproven existing therapies,
then patients may continue to receive
drugs that are harmful without being
helpful.
Moreover, say proponents of placebo
controls, patients can be protected from
harm by “escape” criteria, which call for
withdrawal from the trial if the patient
shows evidence of inadequately controlled disease (5). Other changes in study
design can also be used to minimize the
risk to patients from exposure to placebos
(7).
Yet for all of the controversy over placebo-controlled studies, the amount of
agreement may be greater than the
amount of disagreement. For many studies, people on both sides of the issue
would agree that a placebo control is either necessary or unacceptable. It is only
in a fairly limited area of concern in which
commenters part ways.
Thus, for example, opponents of placebo-controlled trials recognize that placebo controls are justified for “firstgeneration” drugs— drugs designed to fill
a gap in the therapeutic armamentarium.
Relatedly, placebo controls are often justified when there is not adequate evidence
to support the efficacy of existing therapy.
Just as opponents of placebo controls
accept some uses of placebos, proponents
of placebo controls support some limits
on placebo-controlled trials. Basic principles of medical ethics tell us that clinical
studies can go forward only if the expected benefits sufficiently outweigh the
expected risks. Accordingly, acknowledge
the proponents of placebo-controlled tri-
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als, placebo controls are not appropriate
when patients’ health would be placed at
significant risk (8 –10). A placebocontrolled study for a new hairthickening agent could be justified; a
placebo-controlled study for patients
with moderate or severe hypertension
would not be acceptable (11). Similarly, if
an illness causes problems when it goes
untreated for a long period of time, a 52week study with a placebo control is
much more difficult to justify than a
6-week study (12).
When David S.H. Bell (13) explains
why placebo controls are unacceptable
for new drugs to treat type 2 diabetes, he
makes arguments that would resonate
with proponents as well as opponents of
placebo controls. As he observes, patients in
a placebo arm of a study could go 6 months
without effective therapy and thereby suffer significant and irreversible harm.
Still, the very fact that Bell has written
his letter points to a serious concern with
placebo-controlled trials. Apparently,
many are conducted even though they
cannot be justified in terms of widely
shared views about the ethical appropriateness of such trials (2).
There are probably multiple reasons
for the overuse of placebo controls. Pharmaceutical companies may believe it is in
their interest to compare new drugs with
placebo rather than existing therapy, even
when better information for patients and
physicians would be provided by an active control. There also appears to be
some misunderstanding of the U.S. Food
and Drug Administration’s (FDA’s) position on the need for placebo controls
and/or some overly aggressive requiring
of placebo-controlled studies by the FDA.
Whether the FDA is truly at fault is not
always obvious. One article, for example,
criticized the FDA for demanding a placebo-controlled trial of a new anti-anginal
drug, despite a study demonstrating that
the drug was comparable to propranolol
as an anti-anginal agent (2). According to
the FDA, however, the problem with the
study was not necessarily its failure to use
a placebo arm. Rather, the study design
was defective because it left open the possibility that neither the new drug nor pro771
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pranolol was more effective than placebo
in that particular trial (8).
Where do we go from here? Undoubtedly, study sponsors and investigators
need to improve their understanding of
the extent to which placebo controls have
a role in clinical trials. Some studies with
a placebo control should have an active
control instead; other studies with only an
active control also need an arm with a
placebo control.
In addition, institutional review
boards (IRBs) need to demand more of
study investigators who submit proposals
for trials of new drugs. If a placebo arm is
included for a drug that will compete with
an established treatment, the study protocol must supply a persuasive justification
for using a placebo control (2). Similarly,
if a placebo arm is not included, there
must be assurances that the study is designed to avoid the possibility that the
new and active drugs show equal effectiveness but that neither drug would be
more effective than placebo in that study.
IRBs, in other words, must approach
studies of new drugs more skeptically and
approve studies only when they have
enough information to make an independent judgment about the desirability or
undesirability of a placebo control.
In providing the information necessary to justify a placebo control, the
study’s investigators would have to explain why adequate results could not be
obtained by comparing the study drug
with an existing therapy in a welldesigned study with ample subjects, or
why adequate results could not be obtained by using the study drug plus existing therapy in one arm and the existing
therapy plus placebo in the other arm.
Similarly, when a placebo arm is justified,
study investigators would need to explain
why the study does not also include a
third arm with existing therapy.
In some cases, investigators will observe that costs are a consideration in us-
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ing placebo controls, that a placebocontrolled study can often be completed
with fewer subjects and in a shorter period of time (14). Costs are not irrelevant—more expensive studies may mean
fewer desirable studies— but arguments
about costs cannot be accepted automatically. If an IRB is to make judgments on
cost grounds, the board would need specific information about the costs of the
proposed and alternative studies. Indeed,
as a general matter, common arguments
in favor of placebo controls are not adequate to justify a particular use of a placebo control. Rather, the arguments
would have to be based on the specifics of
the study in question.
In deciding whether study investigators have persuasive justification for including or excluding a placebo control,
IRBs should rely on one of the federal government’s basic requirements for medical
research, a requirement that is too often
overlooked. According to regulations for
the “Protection of Human Subjects,” not
only must studies have a favorable benefit-to-risk ratio, but they must be designed so as to have the most favorable
benefit-to-risk ratio possible. In the language of the regulations, an IRB shall not
approve a study unless it is satisfied that
the “[r]isks to subjects are minimized”
(15). In other words, it is not sufficient to
demonstrate relatively low risk; it is also
necessary to demonstrate that risks have
been made as low as possible given the
potential benefits at stake. Thus, if the
same benefits as the proposed study can
be obtained from a different study and the
different study would pose less risk to the
subjects, the IRB must reject the proposed
study. Likewise, if two studies pose the
same risks but one study offers greater
benefit, the study with less benefit should
not be approved. With this requirement
as a guide, IRBs can further refine their
inquiry and better distinguish acceptable
studies from those that are unacceptable.
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